^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD38 positive

    i
    Other names: CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
    Entrez ID:
    952
    Related biomarkers:
    Expression
    Others
    11ms
    Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma. (PubMed, Sci Rep)
    Our findings underscore the influence of extracellular ADO on the neoplastic process of mature B-cell lymphoma. We also propose targeting the CD38-induced-ADO formation pathway, which could serve as a promising therapeutic immune target with multifaceted effects within mature B-cell neoplasms.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD38 expression • PD-1 expression • CD38 positive • CD8 negative
    11ms
    Clinical and Pathological Features of Blastic Plasmacytoid Dendritic Cell Neoplasm (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The immunophenotype of BPDCN is heterogeneous. CD56 is a reliable marker to distinguish neoplastic pDC cells from reactive pDC cells. The BPDCN patients who underwent hematopoietic stem cell transplantation (HSCT) after achieving remission from initial chemotherapy tend to have a better prognosis.
    Retrospective data • Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD36 (thrombospondin receptor) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CD99 (CD99 Molecule)
    |
    CD38 positive • NCAM1 expression
    12ms
    FIL_DALYA: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (clinicaltrials.gov)
    P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    CD38 positive
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1year
    Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study (ASH 2024)
    We recently reported that increased expression of ST3GAL1 was associated with inferior PFS in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed MM patients treated with bortezomib, thalidomide, and dexamethasone (VTd) +/- Dara as induction and consolidation within the CASSIOPEIA study. Conclusions : Within part 2 of CASSIOPEIA, increased expression of ST3GAL1 is significantly associated with inferior PFS and predicts lack of sustained MRD and disease progression in patients MRD negative (10-5) prior to the onset of maintenance therapy or observation. Our preliminary data suggest that desialylation strategies, currently in clinical development, could help achieve deep and durable remissions in MM patients receiving current Dara based quadruplet treatment approaches.
    Clinical • PD(L)-1 Biomarker • IO biomarker • Minimal residual disease
    |
    PD-L1 (Programmed death ligand 1) • SDC1 (Syndecan 1)
    |
    CD38 positive
    |
    clonoSEQ
    |
    bortezomib • dexamethasone • thalidomide
    1year
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=650, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial primary completion date
    |
    CD38 positive
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Tecvayli (teclistamab-cqyv)
    1year
    Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial completion date: Feb 2028 --> Apr 2030
    Enrollment closed • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD200 (CD200 Molecule)
    |
    CD20 positive • CD38 positive
    |
    Venclexta (venetoclax)
    1year
    Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Y-mAbs Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD38 positive
    1year
    Gaucher-like crystal-storing histiocytosis associated with kappa chain myeloma: A case report with next generation sequencing study. (PubMed, Pathol Res Pract)
    Accordingly, this case died of pneumonia with septic shock during treatment. Our findings suggest that the presence of rhomboid crystals in bone marrow smears may alert pathologists to look for the possibility of crystal-storing histiocytosis and the prognosis of patients with multiple myeloma may depend on the genetic features of tumor cells rather than the association with crystal-storing histiocytosis.
    Journal • PARP Biomarker • Next-generation sequencing
    |
    STK11 (Serine/threonine kinase 11) • KDR (Kinase insert domain receptor) • MSH6 (MutS homolog 6) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • SDC1 (Syndecan 1) • CCND3 (Cyclin D3)
    |
    STK11 mutation • CD38 positive • SDC1 positive
    |
    TruSight Oncology 500 Assay
    1year
    Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia. (PubMed, J Hematol)
    The FC analysis of the peripheral blood allowed the rapid characterization of a non-hematological neoplastic cell population, circulating at unusually high frequency and mimicking an acute myeloid leukemia. The FC detection of CD45-negative cell populations in peripheral blood, bone marrow or lymph node aspirate should prompt the setup of an immunophenotyping panel including EpCAM, CD9, CD56 and CD117, to allow for a rapid and accurate identification of ectopic malignant epithelial cells.
    Journal • IO biomarker • Tumor cell
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • SDC1 (Syndecan 1) • CD9 (CD9 Molecule) • TFRC
    |
    CD38 positive • NCAM1 expression • CD9 expression • SDC1 positive • EPCAM expression
    over1year
    CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • IO biomarker
    |
    CD38 positive
    |
    cyclophosphamide • fludarabine IV • CART-BCMA/CS1
    over1year
    PET Imaging Study of 68Ga-NB381 in Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Recruiting, Peking University First Hospital
    New P1 trial • IO biomarker
    |
    CD38 positive
    almost2years
    Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1/2, N=37, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD38 positive
    |
    Blenrep (belantamab mafodotin-blmf)